ADMA vs. BMY
Compare and contrast key facts about ADMA Biologics, Inc. (ADMA) and Bristol-Myers Squibb Company (BMY).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: ADMA or BMY.
Correlation
The correlation between ADMA and BMY is 0.38, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
ADMA vs. BMY - Performance Comparison
Key characteristics
ADMA:
2.94
BMY:
0.42
ADMA:
3.65
BMY:
0.83
ADMA:
1.48
BMY:
1.10
ADMA:
4.58
BMY:
0.25
ADMA:
13.73
BMY:
1.54
ADMA:
15.07%
BMY:
7.80%
ADMA:
71.91%
BMY:
30.47%
ADMA:
-91.28%
BMY:
-70.62%
ADMA:
-13.50%
BMY:
-35.75%
Fundamentals
ADMA:
$5.61B
BMY:
$101.88B
ADMA:
$0.81
BMY:
$2.68
ADMA:
29.04
BMY:
18.68
ADMA:
0.00
BMY:
2.26
ADMA:
13.26
BMY:
2.14
ADMA:
16.08
BMY:
5.92
ADMA:
$344.58M
BMY:
$47.64B
ADMA:
$180.30M
BMY:
$31.43B
ADMA:
$123.41M
BMY:
$16.18B
Returns By Period
In the year-to-date period, ADMA achieves a 23.62% return, which is significantly higher than BMY's -15.29% return. Over the past 10 years, ADMA has outperformed BMY with an annualized return of 10.56%, while BMY has yielded a comparatively lower -0.53% annualized return.
ADMA
23.62%
18.70%
7.51%
209.04%
54.63%
10.56%
BMY
-15.29%
-11.66%
-12.43%
12.63%
-1.61%
-0.53%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
ADMA vs. BMY — Risk-Adjusted Performance Rank
ADMA
BMY
ADMA vs. BMY - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for ADMA Biologics, Inc. (ADMA) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
ADMA vs. BMY - Dividend Comparison
ADMA has not paid dividends to shareholders, while BMY's dividend yield for the trailing twelve months is around 5.20%.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
ADMA ADMA Biologics, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
BMY Bristol-Myers Squibb Company | 5.20% | 4.24% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% | 2.46% |
Drawdowns
ADMA vs. BMY - Drawdown Comparison
The maximum ADMA drawdown since its inception was -91.28%, which is greater than BMY's maximum drawdown of -70.62%. Use the drawdown chart below to compare losses from any high point for ADMA and BMY. For additional features, visit the drawdowns tool.
Volatility
ADMA vs. BMY - Volatility Comparison
ADMA Biologics, Inc. (ADMA) has a higher volatility of 25.35% compared to Bristol-Myers Squibb Company (BMY) at 10.24%. This indicates that ADMA's price experiences larger fluctuations and is considered to be riskier than BMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
ADMA vs. BMY - Financials Comparison
This section allows you to compare key financial metrics between ADMA Biologics, Inc. and Bristol-Myers Squibb Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
ADMA vs. BMY - Profitability Comparison
ADMA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, ADMA Biologics, Inc. reported a gross profit of 63.33M and revenue of 117.55M. Therefore, the gross margin over that period was 53.9%.
BMY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Bristol-Myers Squibb Company reported a gross profit of 8.17B and revenue of 11.20B. Therefore, the gross margin over that period was 72.9%.
ADMA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, ADMA Biologics, Inc. reported an operating income of 38.32M and revenue of 117.55M, resulting in an operating margin of 32.6%.
BMY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Bristol-Myers Squibb Company reported an operating income of 3.52B and revenue of 11.20B, resulting in an operating margin of 31.4%.
ADMA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, ADMA Biologics, Inc. reported a net income of 111.90M and revenue of 117.55M, resulting in a net margin of 95.2%.
BMY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Bristol-Myers Squibb Company reported a net income of 2.46B and revenue of 11.20B, resulting in a net margin of 21.9%.